DE69824039D1 - Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung - Google Patents
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregungInfo
- Publication number
- DE69824039D1 DE69824039D1 DE69824039T DE69824039T DE69824039D1 DE 69824039 D1 DE69824039 D1 DE 69824039D1 DE 69824039 T DE69824039 T DE 69824039T DE 69824039 T DE69824039 T DE 69824039T DE 69824039 D1 DE69824039 D1 DE 69824039D1
- Authority
- DE
- Germany
- Prior art keywords
- fusion proteins
- fused
- subunit
- fusion protein
- heterodimary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98699797A | 1997-12-08 | 1997-12-08 | |
US986997 | 1997-12-08 | ||
PCT/US1998/025978 WO1999029732A2 (en) | 1997-12-08 | 1998-12-08 | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69824039D1 true DE69824039D1 (de) | 2004-06-24 |
DE69824039T2 DE69824039T2 (de) | 2005-08-18 |
Family
ID=25532973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69824039T Expired - Lifetime DE69824039T2 (de) | 1997-12-08 | 1998-12-08 | Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung |
Country Status (11)
Country | Link |
---|---|
US (4) | US6838260B2 (de) |
EP (2) | EP1037927B1 (de) |
JP (2) | JP4336452B2 (de) |
AT (1) | ATE267215T1 (de) |
AU (1) | AU763719B2 (de) |
CA (2) | CA2693296C (de) |
DE (1) | DE69824039T2 (de) |
DK (1) | DK1037927T3 (de) |
ES (2) | ES2590912T3 (de) |
PT (1) | PT1037927E (de) |
WO (1) | WO1999029732A2 (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
AU763719B2 (en) * | 1997-12-08 | 2003-07-31 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
PL343462A1 (en) * | 1998-04-15 | 2001-08-13 | Lexigen Pharm Corp | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
BR0010725A (pt) * | 1999-05-19 | 2002-02-19 | Lexigen Pharm Corp | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
HUP0202442A3 (en) * | 1999-08-09 | 2005-01-28 | Lexigen Pharmaceuticals Corp L | Multiple cytokine-antibody complexes |
EP1731531B1 (de) | 1999-08-09 | 2012-05-30 | Merck Patent GmbH | Mehrere Zytokin-Antikörper Komplexe |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
AU4314801A (en) | 2000-02-11 | 2001-08-20 | Lexigen Pharm Corp | Enhancing the circulating half-life of antibody-based fusion proteins |
ES2484966T3 (es) * | 2000-04-12 | 2014-08-12 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
DK1294401T3 (da) * | 2000-06-29 | 2007-10-08 | Merck Patent Gmbh | Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler |
US6911204B2 (en) | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US7507413B2 (en) * | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050054051A1 (en) * | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
DK1383785T3 (da) * | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Rekombinant tumorspecifikt antistof og anvendelse deraf |
CA2453986A1 (en) * | 2001-07-18 | 2003-01-30 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Glycoprotein vi fusion proteins |
MXPA04005266A (es) | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
EP1463752A4 (de) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | Albuminfusionsproteine |
WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1418184A1 (de) * | 2002-11-08 | 2004-05-12 | Cell Center Cologne GmbH | Aus den p40 und p35 Untereinheiten des IL-12 und ein ScFv bestehendes rekombinantes Protein und seine Verwendung |
AU2003298187B2 (en) | 2002-12-17 | 2010-09-16 | Merck Patent Gmbh | Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2 |
JP4988333B2 (ja) * | 2003-04-30 | 2012-08-01 | ユニバーシティー オブ チューリッヒ | 免疫毒素を用いる癌を処置するための方法 |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
PL1699822T3 (pl) * | 2003-12-30 | 2008-08-29 | Merck Patent Gmbh | Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie |
CA2551916C (en) * | 2003-12-31 | 2014-04-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Fc-erythropoietin fusion protein with improved pharmacokinetics |
EA011859B9 (ru) * | 2004-01-05 | 2013-07-30 | Емд Лексиген Ресерч Сентер Корп. | Соединения для адресной доставки препарата к ткани или органу-мишени |
EP1706428B1 (de) * | 2004-01-22 | 2009-09-23 | MERCK PATENT GmbH | Antikrebs-antikörper mit reduzierter komplementfixierung |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
ES2342964T3 (es) * | 2004-12-09 | 2010-07-20 | Merck Patent Gmbh | Variantes de la interleucina-7 con inmunogenicidad reducida. |
JP2008543278A (ja) * | 2005-05-11 | 2008-12-04 | フィロゲン エスピーエー | フィブロネクチンed−bに対する抗体l19とインターロイキン12との融合タンパク質 |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
BRPI0620648B1 (pt) * | 2005-12-30 | 2022-12-20 | Merck Patent Gesellschaft Mit Beschrãnkter Haftung | Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma |
DK1966245T3 (da) | 2005-12-30 | 2011-07-18 | Merck Patent Gmbh | Anti-CD19-Antistoffer med reduceret immunogenicitet |
JP5368301B2 (ja) * | 2006-06-22 | 2013-12-18 | ノボ・ノルデイスク・エー/エス | 可溶性ヘテロ二量体レセプター及びその使用 |
CN102405230A (zh) | 2009-04-22 | 2012-04-04 | 默克专利有限公司 | 具有修饰的FcRn结合位点的抗体融合蛋白 |
WO2011020783A2 (en) * | 2009-08-17 | 2011-02-24 | Roche Glycart Ag | Targeted immunoconjugates |
US20110165122A1 (en) * | 2009-11-10 | 2011-07-07 | The Regents Of The University Of California | Method for targeted and sustained antiviral therapy |
CN103476433A (zh) | 2011-02-10 | 2013-12-25 | 罗切格利卡特公司 | 改良的免疫疗法 |
WO2012178137A1 (en) | 2011-06-24 | 2012-12-27 | Gillies Stephen D | Light chain immunoglobulin fusion proteins and methods of use thereof |
ES2888249T3 (es) * | 2011-10-11 | 2022-01-03 | Univ Zuerich | Medicamento de combinación que comprende IL-12 y un agente para el bloqueo de moléculas inhibidoras de linfocitos T para terapia tumoral |
US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
SG11201602170XA (en) | 2013-10-02 | 2016-04-28 | Viventia Bio Inc | Anti-epcam antibodies and methods of use |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CN105543279A (zh) * | 2014-10-30 | 2016-05-04 | 常州卡斯比生物科技有限公司 | 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂 |
US10576163B2 (en) | 2015-03-12 | 2020-03-03 | Viventia Bio Inc. | Methods of treatment for EpCAM positive bladder cancer |
US10583198B2 (en) | 2015-03-12 | 2020-03-10 | Viventia Bio Inc. | Dosing strategies for targeting EPCAM positive bladder cancer |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018030806A1 (ko) * | 2016-08-10 | 2018-02-15 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
EP3511340A4 (de) * | 2016-08-10 | 2020-03-18 | Ajou University Industry-Academic Cooperation Foundation | An immunoglobulin-fc heterodimer kondensiertes zytokin und pharmazeutische zusammensetzung damit |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
US11471490B2 (en) | 2017-07-03 | 2022-10-18 | Torque Therapeutics, Inc. | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof |
WO2019129053A1 (zh) * | 2017-12-26 | 2019-07-04 | 南京金斯瑞生物科技有限公司 | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 |
CN110396133B (zh) * | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
WO2019246508A1 (en) | 2018-06-21 | 2019-12-26 | Shattuck Labs, Inc. | Heterodimeric proteins and uses thereof |
US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
JP2022503959A (ja) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | Il-12ヘテロ二量体fc-融合タンパク質 |
BR112021007175A2 (pt) | 2018-10-23 | 2021-08-10 | Dragonfly Therapeutics, Inc. | proteínas fundidas a fc heterodimérico |
KR102524247B1 (ko) * | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3의 복합체 및 이의 용도 |
CA3141626A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
AU2020353235A1 (en) * | 2019-09-28 | 2022-03-31 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
WO2021067863A2 (en) | 2019-10-03 | 2021-04-08 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
AU2021248919A1 (en) * | 2020-04-01 | 2022-10-13 | Xilio Development, Inc. | Masked IL-12 cytokines and their cleavage products |
WO2024086739A1 (en) | 2022-10-20 | 2024-04-25 | Synthekine, Inc. | Methods and compositions of il12 muteins and il2 muteins |
Family Cites Families (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4469797A (en) | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
EP0158198A1 (de) | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | DNA und ihre Verwendung |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US5679543A (en) | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
US5643565A (en) | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
DE3712985A1 (de) | 1987-04-16 | 1988-11-03 | Hoechst Ag | Bifunktionelle proteine |
US5359035A (en) | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
EP0237019A3 (de) | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Konjugiertes Interferon und dessen Herstellung unter Verwendung eines rekombinanten Gens |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
US4894227A (en) | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5508031A (en) | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
EP0307434B2 (de) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Geänderte antikörper |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
EP0623679B1 (de) | 1987-05-21 | 2003-06-25 | Micromet AG | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
ATE122238T1 (de) | 1987-06-10 | 1995-05-15 | Dana Farber Cancer Inst Inc | Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. |
US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
ES2054753T3 (es) | 1987-09-02 | 1994-08-16 | Ciba Geigy Ag | Conjugados de citoquinas con inmunoglobulinas. |
JP2755395B2 (ja) | 1987-09-23 | 1998-05-20 | ブリストル―マイアーズ スクイブ コムパニー | Hiv感染細胞に殺作用する抗体異種結合体 |
NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
PT89121A (pt) | 1987-12-04 | 1989-12-29 | Du Pont | Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
US5120525A (en) | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
US4975369A (en) * | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
IE62463B1 (en) | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US6750329B1 (en) * | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
US6291158B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
EP0406857B1 (de) | 1989-07-07 | 1995-05-24 | Takeda Chemical Industries, Ltd. | Proteine und deren Herstellung |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
EP0790309B1 (de) | 1989-12-22 | 2007-07-25 | F. Hoffmann-La Roche Ag | Zytotoxischer Lymphozyten-Reifefaktor 40kD Untereinheit und monoklonale Antikörper spezifisch dafür |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
EP0574395B1 (de) * | 1990-11-09 | 2002-06-12 | GILLIES, Stephen D. | Cytokine immunokonjugate |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
WO1993005169A1 (en) | 1991-08-30 | 1993-03-18 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
US20020037558A1 (en) | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
US6627615B1 (en) * | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
DK0633929T3 (da) | 1992-04-01 | 2004-06-28 | Univ Rockefeller | Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener |
WO1993024135A1 (en) * | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
JP3285355B2 (ja) * | 1992-06-04 | 2002-05-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | invivo遺伝子治療のための方法及び組成物 |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
DE4228839A1 (de) | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
DE69232604T2 (de) * | 1992-11-04 | 2002-11-07 | City Of Hope Duarte | Antikörperkonstrukte |
WO1994009820A1 (en) | 1992-11-05 | 1994-05-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US5738849A (en) | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
US5543297A (en) | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
US5888772A (en) | 1993-04-29 | 1999-03-30 | Abbott Laboratories | DNA encoding human a erythropoietin analog |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
CA2125763C (en) | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
GB9316989D0 (en) * | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
IL192290A0 (en) | 1993-08-17 | 2008-12-29 | Kirin Amgen Inc | Erythropoietin analogs |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
CN1309833C (zh) | 1994-04-26 | 2007-04-11 | 儿童医学中心公司 | 血管生成抑制素及其在制备药物中的用途 |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
ES2167391T3 (es) | 1994-09-16 | 2002-05-16 | Merck Patent Gmbh | Inmunoconjugados ii. |
EP1621206A1 (de) * | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimäre Zytokine und ihre Verwendung |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
EP0815224B1 (de) | 1995-03-10 | 2004-07-21 | Genentech, Inc. | Die aktivierung von rezeptoren durch gas6 |
US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
EA199800104A1 (ru) | 1995-06-30 | 1998-10-29 | Эли Лилли Энд Компани | Способ лечения диабета |
US6406689B1 (en) | 1995-10-03 | 2002-06-18 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
AU1407997A (en) * | 1995-12-01 | 1997-06-19 | Beth Israel Hospital | Il-12 p40 subunit fusion polypeptides and uses thereof |
US6620413B1 (en) * | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
AU2527397A (en) * | 1996-03-13 | 1997-10-01 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
CA2205757C (en) | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
US5922685A (en) | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
ES2176574T3 (es) | 1996-09-03 | 2002-12-01 | Gsf Forschungszentrum Umwelt | Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral. |
US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
US6100387A (en) | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
DK0973550T3 (da) | 1997-04-11 | 2003-02-10 | Searle & Co | Antagonistiske anti-AVB3-integrin-antistoffer |
AU763719B2 (en) | 1997-12-08 | 2003-07-31 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
PL343462A1 (en) * | 1998-04-15 | 2001-08-13 | Lexigen Pharm Corp | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
MXPA00010151A (es) | 1998-04-17 | 2002-08-06 | Lexigen Pharm Corp | Mejoramiento de las respuestas inmunes mediadas por proteina de fusion de anticuerpo-citocina mediante la soadministracion con inhibidores de prostaglandina. |
US6284536B1 (en) | 1998-04-20 | 2001-09-04 | The Regents Of The University Of California | Modified immunoglobin molecules and methods for use thereof |
CA2328490A1 (en) | 1998-05-14 | 1999-11-18 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Fused protein |
US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
CN101386651A (zh) | 1998-08-25 | 2009-03-18 | 默克专利股份公司 | 表达以及分泌制管张素和内皮抑制素的免疫融合物 |
US6646113B1 (en) | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
US6335176B1 (en) | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
WO2000040615A2 (en) | 1999-01-07 | 2000-07-13 | Lexigen Pharmaceuticals, Corp. | EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS |
MXPA01011250A (es) | 1999-05-06 | 2002-08-12 | Univ Wake Forest | Composiciones y metodos para identificar antigenos que producen una respuesta inmune. |
US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
BR0010725A (pt) | 1999-05-19 | 2002-02-19 | Lexigen Pharm Corp | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc |
CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
HUP0202442A3 (en) * | 1999-08-09 | 2005-01-28 | Lexigen Pharmaceuticals Corp L | Multiple cytokine-antibody complexes |
AU4314801A (en) | 2000-02-11 | 2001-08-20 | Lexigen Pharm Corp | Enhancing the circulating half-life of antibody-based fusion proteins |
DE60121733T2 (de) * | 2000-02-24 | 2007-08-09 | Philogen S.P.A. | Zusamensetzungen und Verfahren zur Behandlung von Angiogenese in pathologischen Schädigungen |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
US20020019342A1 (en) | 2000-05-12 | 2002-02-14 | Robert Bayer | In vitro modification of glycosylation patterns of recombinant glycopeptides |
DK1294401T3 (da) | 2000-06-29 | 2007-10-08 | Merck Patent Gmbh | Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler |
EP1392826A2 (de) | 2001-01-18 | 2004-03-03 | MERCK PATENT GmbH | Bifunktionelle fusionsproteine mit glukocerebrosidase-aktivität |
KR20040074587A (ko) * | 2001-02-19 | 2004-08-25 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 인공 단백질 |
CN100404673C (zh) * | 2001-02-19 | 2008-07-23 | 默克专利有限公司 | 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途 |
DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
DK1383785T3 (da) | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Rekombinant tumorspecifikt antistof og anvendelse deraf |
MXPA04005266A (es) | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
JP3712985B2 (ja) | 2002-02-22 | 2005-11-02 | アンリツ株式会社 | 直交変調器のキャリアリーク調整点検出方法、そのキャリアリーク調整方法、及び直交変調装置 |
AU2003298187B2 (en) * | 2002-12-17 | 2010-09-16 | Merck Patent Gmbh | Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2 |
DE10310387B3 (de) | 2003-03-07 | 2004-07-22 | Heraeus Electro-Nite International N.V. | Messeinrichtung zur Bestimmung der Sauerstoffaktivität in Metall- oder Schlackeschmelzen |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
-
1998
- 1998-12-08 AU AU17160/99A patent/AU763719B2/en not_active Expired
- 1998-12-08 WO PCT/US1998/025978 patent/WO1999029732A2/en active IP Right Grant
- 1998-12-08 EP EP98961978A patent/EP1037927B1/de not_active Expired - Lifetime
- 1998-12-08 EP EP04011760.8A patent/EP1489100B1/de not_active Expired - Lifetime
- 1998-12-08 ES ES04011760.8T patent/ES2590912T3/es not_active Expired - Lifetime
- 1998-12-08 AT AT98961978T patent/ATE267215T1/de active
- 1998-12-08 DE DE69824039T patent/DE69824039T2/de not_active Expired - Lifetime
- 1998-12-08 ES ES98961978T patent/ES2221717T3/es not_active Expired - Lifetime
- 1998-12-08 JP JP2000524321A patent/JP4336452B2/ja not_active Expired - Lifetime
- 1998-12-08 CA CA2693296A patent/CA2693296C/en not_active Expired - Lifetime
- 1998-12-08 DK DK98961978T patent/DK1037927T3/da active
- 1998-12-08 PT PT98961978T patent/PT1037927E/pt unknown
- 1998-12-08 CA CA2312188A patent/CA2312188C/en not_active Expired - Lifetime
-
2001
- 2001-12-04 US US10/005,212 patent/US6838260B2/en not_active Expired - Lifetime
-
2004
- 2004-09-07 US US10/935,532 patent/US7226998B2/en not_active Expired - Fee Related
-
2007
- 2007-05-21 US US11/804,895 patent/US7576193B2/en not_active Expired - Fee Related
-
2008
- 2008-12-12 JP JP2008317739A patent/JP2009149640A/ja active Pending
-
2009
- 2009-07-07 US US12/498,491 patent/US7879319B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20020193570A1 (en) | 2002-12-19 |
JP2001525423A (ja) | 2001-12-11 |
DK1037927T3 (da) | 2004-09-06 |
EP1489100B1 (de) | 2016-06-15 |
ES2221717T3 (es) | 2005-01-01 |
PT1037927E (pt) | 2004-10-29 |
EP1037927A2 (de) | 2000-09-27 |
AU1716099A (en) | 1999-06-28 |
US6838260B2 (en) | 2005-01-04 |
WO1999029732A2 (en) | 1999-06-17 |
EP1489100A3 (de) | 2012-06-06 |
US20080311655A1 (en) | 2008-12-18 |
JP4336452B2 (ja) | 2009-09-30 |
EP1037927B1 (de) | 2004-05-19 |
EP1489100A2 (de) | 2004-12-22 |
US20100015089A1 (en) | 2010-01-21 |
CA2693296C (en) | 2013-09-10 |
ES2590912T3 (es) | 2016-11-24 |
DE69824039T2 (de) | 2005-08-18 |
AU763719B2 (en) | 2003-07-31 |
US7226998B2 (en) | 2007-06-05 |
US20050137384A1 (en) | 2005-06-23 |
CA2312188A1 (en) | 1999-06-17 |
CA2693296A1 (en) | 1999-06-17 |
WO1999029732A3 (en) | 1999-08-26 |
ATE267215T1 (de) | 2004-06-15 |
CA2312188C (en) | 2010-06-29 |
JP2009149640A (ja) | 2009-07-09 |
US7879319B2 (en) | 2011-02-01 |
US7576193B2 (en) | 2009-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69824039D1 (de) | Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung | |
DK0471011T3 (da) | Humant lactoferrin-cDNA-sekvens | |
DE3480939D1 (de) | Vektoren zur transformation von hefe. | |
ATE117375T1 (de) | Transduktionsveränderte fibroblasten und ihre anwendung. | |
DE69024291T2 (de) | Rezeptoren für Tumornekrosisfaktor-alpha und -beta | |
DE69530374T2 (de) | Blutbildendes fusionprotein mit il-3 varianten | |
DE69022559T2 (de) | Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I). | |
DK0673420T3 (da) | Mammale receptorer for interleukin 10 (IL-10) | |
ES8506347A1 (es) | Un metodo para producir un polipeptido de tipo il-2-". | |
DE59610519D1 (de) | Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragment-Fusionsmolekülen in E. coli | |
DE69939330D1 (de) | Wachstumsfaktor-homologe zvegf-3 | |
DE60142446D1 (de) | Verbesserung der homogenität und sekretion von rekombinanten proteinen in säugetiersystemen | |
AU8110487A (en) | DNA molecules coding for proteins targeted to plant cell walls | |
ATE142264T1 (de) | Rekombinante herstellung von a-ketten- polypeptiden von pdgf | |
DK0639225T3 (da) | Nye polypeptider og peptider, nucleinsyrer, der koder for dem, og deres anvendelse i området tumorterapi, inflammation eller immunologi | |
PE42695A1 (es) | Procedimiento para producir proteina c | |
ATE109827T1 (de) | Verfahren zur herstellung von peptiden, dazu zu verwendendes rekombinantes plasmid und mit diesem plasmid transformierte myelomzellen. | |
ES2012283A6 (es) | Procedimiento de obtencion de una proteina de endotoxina de efecto insecticida. | |
Al Nasar Ahmed Sehgala Peter et al. | Clinical Immunology–Review Article | |
DE3752281D1 (de) | Stabilisierung von messenger-rns in tierischen zellen | |
DE69932644D1 (de) | Menschliches Protein mit in vitro antiproliferativer Aktivität. | |
Mohr et al. | Degree of O-and N-glycosylation of lymphokines released from A 23187-/TPA-induced lymphocytes varies differently with culture time |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: MERCK PATENT GMBH, 64293 DARMSTADT, DE |